胃がんの世界市場

胃がんの世界市場は2030年までに84億米ドルに到達

2024年に33億米ドルと推定される胃がんの世界市場は、2024～2030年の分析期間においてCAGR 16.9%で成長し、2030年には84億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである腺がんは、CAGR 14.8％を記録し、分析期間終了時には24億米ドルに達すると予測されます。リンパ腫分野の成長率は、分析期間のCAGRで19.0％と推定されます。

米国市場は8億9,310万米ドルと推定、中国はCAGR 21.9％で成長予測

米国の胃がん市場は、2024年に8億9,310万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに18億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは21.9%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ12.8％と15.1％と予測されています。欧州では、ドイツがCAGR約13.4%で成長すると予測されています。

世界の胃がん市場- 主要動向と促進要因のまとめ

胃がん調査が世界ヘルスにとってより重要になっているのはなぜか？

胃がんは、特に東アジア、中・東欧、南米の一部などの地域において、依然として世界のがん関連死の主要原因の1つとなっています。その世界の健康負担に対する認識の高まりが、早期発見と治療法の大幅な進歩に拍車をかけています。胃がんは、治療の選択肢が限られ、生存率が低い進行期に診断されることが多いため、特に課題となっています。このため、バイオマーカー検査や高度な画像診断技術など、早期診断ツールや技術に注目が集まり、病気を最も早い段階で特定することが重要視されています。さらに、ターゲットとなる治療法を特定するために不可欠な、胃がん発症の根底にある分子メカニズムの解明がますます重視されるようになっています。特に、ヘリコバクター・ピロリ菌感染、遺伝子変異、食事因子の役割に関する調査は、これらがこの疾患の重要な危険因子であることが確認されたため、勢いを増しています。その結果、治療法を進歩させ、患者の予後を改善するために、公的および民間の医療機関の支援を受けて、調査への資金が増加しています。胃がんという病気とその複雑な性質に対する世界の認識の高まりとともに、科学者たちは免疫療法、精密医療、個別化がん治療などの新しい治療アプローチを模索しており、これらすべてが胃がんとの闘いにおける技術革新の原動力となっています。

治療の進歩は胃がんの状況をどのように形成しているか？

胃がんの治療状況は、過去10年間で大きく進化し、外科的技術と全身療法の両方が進歩し、患者に新たな希望をもたらしています。以前は、手術が早期胃がんの主な治療法であったが、診断時に根治手術の適応となる患者はごく一部でした。しかし、低侵襲手術の出現により、患者はより侵襲の少ない手術を受けられるようになり、回復に要する時間が短縮され、術後の転帰も改善されるようになりました。手術に加え、化学療法、放射線療法、標的療法は、特に進行期の胃がんでは、治療レジメンの不可欠な要素となっています。トラスツズマブ（ハーセプチン）などの標的療法は、胃がん症例のかなりの割合を占めるHER2陽性胃がんの治療に有効性を示しています。さらに最近では、特に進行胃がん患者に対する有望な治療法として免疫療法が登場しています。ペムブロリズマブ（キイトルーダ）などの免疫チェックポイント阻害剤は有望な結果を示しており、他の治療選択肢を使い果たした患者に新たな道を提供しています。さらに、分子プロファイリングや遺伝子検査の進歩により、個人の腫瘍の特徴に合わせたより個別化された治療計画が可能になりつつあります。より多くの治療法が利用できるようになるにつれて、より良い治療成績を得るためにこれらの治療法を組み合わせることに焦点が当てられるようになってきており、二重療法、免疫療法と化学療法の併用、その他の相乗的な治療法の有用性を検討する臨床試験が活発に行われています。

胃がんの罹患率増加の主な要因は何か？

胃がんの世界の罹患率の増加にはいくつかの要因が寄与しており、ライフスタイルや環境の影響が病気の発症に重要な役割を果たしています。主な危険因子の一つは、慢性炎症を引き起こし、胃がんのリスクを高めることが知られているヘリコバクター・ピロリ菌への感染です。ピロリ菌感染は特に新興諸国に多いが、衛生環境の改善や治療法の進歩により、先進国ではその有病率が減少しています。しかし、食生活の乱れ、喫煙、飲酒など、その他の生活習慣に関連する要因は、胃がんの罹患率上昇の主な原因となっています。世界の多くの地域で一般的な塩漬け、燻製、漬け物などの多い食生活は、胃がんのリスク上昇に関連しています。さらに、肥満と運動不足は、発がんに寄与する炎症を増加させ、腸内細菌叢を変化させることが知られているため、重要な危険因子として浮上しています。遺伝的素因も一役買っており、遺伝性びまん性症候群（HDGC）のような特定の遺伝性症候群は、個人をより高いリスクにさらします。さらに、年齢も重要な要素であり、胃がんの開発リスクは50歳以上で著しく増加します。したがって、胃がんの発症率の増加は、早期発見と進行段階での効果的な治療能力という課題とともに、環境、食事、遺伝、ライフスタイルの複合的な要因に起因しています。

胃がん治療市場成長の主な促進要因は？

胃がん治療市場の成長は、医学研究の進歩、ヘルスケア投資の増加、一般市民の意識の高まりなど、いくつかの重要な要因によってもたらされます。胃がんの罹患率は、特に高齢化が進む国やヘリコバクター・ピロリ感染率の高い国で上昇を続けており、効果的な治療に対する需要は加速しています。特に発展途上国における医療アクセスの拡大も、治療を求める患者数の増加に寄与しています。早期診断は依然として重要な課題であるが、より高度なスクリーニングや診断ツールの開発により、一部の地域では早期発見が可能になり、治療がより効果的になり、生存率が向上しています。個別化医療と精密腫瘍学への注目の高まりも大きな推進力であり、治療は個人の遺伝的・分子的プロファイルに合わせたものとなり、より効果的で的を絞った治療へとつながっています。バイオマーカーと分子診断学の統合により、医師は腫瘍の特異的な特徴に基づき、どの治療が患者に最も利益をもたらす可能性が高いかを特定できるようになりつつあります。さらに、免疫療法への関心の高まりと胃がんへの応用も市場成長を促進する重要な要因です。がん細胞と闘うために身体の免疫システムを利用する免疫療法は、進行性または転移性の胃がん患者の治療に有望であり、その開発が市場の成長を加速しています。さらに、製薬業界が新規治療法や併用療法レジメンの開発にますます注力していることや、胃がんに特化した臨床試験の数が増加していることも、継続的な進歩と患者の予後改善に寄与し、胃がん治療市場をさらに牽引すると予想されます。

セグメント

疾患タイプ（腺がん、リンパ腫、消化管間質腫瘍、カルチノイド腫瘍、その他の疾患タイプ）、治療タイプ（免疫療法、標的療法、化学療法、放射線療法および外科療法）、薬剤クラス別（PD-1/PD-L1阻害剤、HER2アンタゴニスト、VEGFR2アンタゴニスト、その他の薬剤クラス）、投与経路（経口剤、注射剤）、流通チャネル（専門薬局・小売薬局、病院薬局、その他の流通チャネル）

調査対象企業の例（注目の48社）

• Amgen Inc.
• Astellas Pharma Inc.
• AstraZeneca plc
• Bayer AG
• BeiGene Ltd.
• Biohit Oyj
• Bristol-Myers Squibb Company
• Celltrion Healthcare Co., Ltd.
• Eli Lilly and Company
• Exalenz Bioscience Ltd.
• F. Hoffmann-La Roche Ltd.
• GeneMatrix Inc.
• GSK plc
• Imugene Limited
• Jiangsu Hengrui Medicine Co.
• Merck & Co., Inc.
• Novartis AG
• OBI Pharma, Inc.
• Pfizer Inc.
• Samsung Bioepis Co., Ltd.

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、人為的な売上原価の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

Global Industry Analystsは、世界の主要なチーフ・エコノミスト（1万4,949人）、シンクタンク（62団体）、貿易・産業団体（171団体）の専門家の意見に熱心に従いながら、エコシステムへの影響を評価し、新たな市場の現実に対処しています。あらゆる主要国の専門家やエコノミストが、関税とそれが自国に与える影響についての意見を追跡調査しています。

Global Industry Analystsは、この混乱が今後2-3ヶ月で収束し、新しい世界秩序がより明確に確立されると予想しています。Global Industry Analystsは、これらの開発をリアルタイムで追跡しています。

2025年4月：交渉フェーズ

4月のリリースでは、世界市場全体に対する関税の影響を取り上げ、地域別の市場調整について紹介します。当社の予測は、過去のデータと進化する市場影響要因に基づいています。

2025年7月：最終関税リセット

無料アップデート弊社のお客様には、各国間で最終リセットが発表された後、7月に無料アップデート版をお届けします。最終アップデート版には、明確に定義された関税影響分析が組み込まれています。

相互および二国間貿易と関税の影響分析：

アメリカ <>中国<>メキシコ <>カナダ <>EU <>日本<>インド <>その他176カ国

業界をリードするエコノミスト：Global Industry Analystsの知識ベースは、国家、シンクタンク、貿易・業界団体、大企業、そして世界の計量経済状況におけるこの前例のないパラダイムシフトの影響を共有する領域の専門家など、最も影響力のあるチーフエコノミストを含む1万4,949人のエコノミストを追跡しています。当社の16,491を超えるレポートのほとんどは、マイルストーンに基づくこの2段階のリリーススケジュールを取り入れています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Gastric Cancer Market to Reach US$8.4 Billion by 2030

The global market for Gastric Cancer estimated at US$3.3 Billion in the year 2024, is expected to reach US$8.4 Billion by 2030, growing at a CAGR of 16.9% over the analysis period 2024-2030. Adenocarcinoma, one of the segments analyzed in the report, is expected to record a 14.8% CAGR and reach US$2.4 Billion by the end of the analysis period. Growth in the Lymphoma segment is estimated at 19.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$893.1 Million While China is Forecast to Grow at 21.9% CAGR

The Gastric Cancer market in the U.S. is estimated at US$893.1 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.8 Billion by the year 2030 trailing a CAGR of 21.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 12.8% and 15.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 13.4% CAGR.

Global Gastric Cancer Market - Key Trends & Drivers Summarized

Why Is Gastric Cancer Research Becoming More Critical for Global Health?

Gastric cancer remains one of the leading causes of cancer-related deaths worldwide, particularly in regions such as East Asia, Central and Eastern Europe, and parts of South America. The increasing recognition of its global health burden has spurred significant advancements in both early detection and treatment options. Gastric cancer is particularly challenging because it is often diagnosed at an advanced stage when treatment options are limited, and survival rates are low. This has led to a growing focus on early diagnostic tools and technologies, such as biomarker testing and advanced imaging techniques, to identify the disease at its earliest stages. Furthermore, there is an increasing emphasis on understanding the molecular mechanisms underlying gastric cancer development, which is crucial for identifying targeted therapies. In particular, research into the role of Helicobacter pylori infection, genetic mutations, and dietary factors has gained momentum, as these are identified as key risk factors for the disease. As a result, funding for gastric cancer research has risen, supported by both public and private health organizations, to advance treatment methods and improve patient outcomes. With the rise in global awareness of the disease and its complex nature, scientists are exploring new therapeutic approaches such as immunotherapy, precision medicine, and personalized cancer treatments, all of which are driving innovations in the fight against gastric cancer.

How Are Advances in Treatment Shaping the Gastric Cancer Landscape?

The treatment landscape for gastric cancer has evolved significantly over the past decade, with advancements in both surgical techniques and systemic therapies offering new hope for patients. In the past, surgery was the main treatment option for early-stage gastric cancer, but only a small percentage of patients were candidates for curative surgery at the time of diagnosis. However, with the advent of minimally invasive procedures, patients are now able to undergo less invasive surgeries, which reduce recovery times and improve post-operative outcomes. In addition to surgery, chemotherapy, radiation therapy, and targeted therapies have become essential components of the treatment regimen, particularly for advanced stages of gastric cancer. Targeted therapies, such as trastuzumab (Herceptin), have shown efficacy in treating HER2-positive gastric cancers, which make up a significant proportion of gastric cancer cases. More recently, immunotherapy has emerged as a promising treatment option, particularly for patients with advanced gastric cancer. Immune checkpoint inhibitors such as pembrolizumab (Keytruda) have demonstrated encouraging results, offering new avenues for patients who have exhausted other treatment options. Moreover, advancements in molecular profiling and genetic testing are allowing for more personalized treatment plans tailored to an individual’s specific tumor characteristics. As more therapies become available, there is an increased focus on combining these modalities for better outcomes, with clinical trials actively investigating the benefits of dual therapies, immunotherapy combined with chemotherapy, and other synergistic approaches to treating gastric cancer.

What Are the Key Factors Contributing to the Increasing Incidence of Gastric Cancer?

Several factors are contributing to the increasing global incidence of gastric cancer, with lifestyle and environmental influences playing a significant role in disease development. One of the major risk factors is infection with Helicobacter pylori, a bacterium that is known to cause chronic inflammation and increase the risk of gastric cancer. H. pylori infection is particularly prevalent in developing countries, but with better sanitation and medical treatments, its prevalence is decreasing in developed nations. However, other lifestyle-related factors, such as poor diet, smoking, and alcohol consumption, continue to be major contributors to the rising incidence of gastric cancer. Diets rich in salted, smoked, or pickled foods, which are common in many parts of the world, have been linked to an increased risk of gastric cancer. Additionally, obesity and lack of physical activity are emerging as significant risk factors, as they are known to increase inflammation and alter gut microbiota, both of which contribute to carcinogenesis. Genetic predisposition also plays a role, with certain inherited syndromes, such as hereditary diffuse gastric cancer (HDGC), putting individuals at higher risk. Additionally, age is a significant factor, with the risk of developing gastric cancer increasing significantly in individuals over 50. The rise in the incidence of gastric cancer can therefore be attributed to a combination of environmental, dietary, genetic, and lifestyle factors, along with the challenges of early detection and the ability to effectively treat the disease in its advanced stages.

What Are the Key Drivers Behind the Growth of the Gastric Cancer Treatment Market?

The growth of the gastric cancer treatment market is driven by several key factors, including advancements in medical research, increasing healthcare investments, and rising public awareness. As the incidence of gastric cancer continues to rise, particularly in countries with aging populations or high rates of Helicobacter pylori infection, the demand for effective treatments is accelerating. The expansion of healthcare access, especially in developing countries, is also contributing to a larger patient population seeking treatment. Early diagnosis remains a significant challenge, but the development of more advanced screening and diagnostic tools has led to earlier detection in some regions, making treatment more effective and improving survival rates. The increasing focus on personalized medicine and precision oncology is another major driver, as treatments are becoming more tailored to an individual’s genetic and molecular profile, leading to more effective and targeted therapies. The integration of biomarkers and molecular diagnostics is enabling physicians to identify which treatments are most likely to benefit patients based on their tumor’s specific characteristics. Additionally, the growing interest in immunotherapy and its application to gastric cancer is another key factor propelling market growth. Immunotherapies, which harness the body’s immune system to fight cancer cells, are showing promise in treating patients with advanced or metastatic gastric cancer, and their development is accelerating the growth of the market. Furthermore, the pharmaceutical industry’s increasing focus on developing novel therapies and combination treatment regimens, as well as the rising number of clinical trials dedicated to gastric cancer, is expected to contribute to continued advancements and better patient outcomes, further driving the gastric cancer treatment market.

SCOPE OF STUDY:

The report analyzes the Gastric Cancer market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Disease Type (Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor, Other Disease Types); Treatment Type (Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy & Surgery); Drug Class (PD-1 / PD-L1 Inhibitors, HER2 Antagonists, VEGFR2 Antagonists, Other Drug Classes); Administration Route (Oral, Injectable); Distribution Channel (Specialty & Retail Pharmacies, Hospital Pharmacies, Other Distribution Channels)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 48 Featured) -

• Amgen Inc.
• Astellas Pharma Inc.
• AstraZeneca plc
• Bayer AG
• BeiGene Ltd.
• Biohit Oyj
• Bristol-Myers Squibb Company
• Celltrion Healthcare Co., Ltd.
• Eli Lilly and Company
• Exalenz Bioscience Ltd.
• F. Hoffmann-La Roche Ltd.
• GeneMatrix Inc.
• GSK plc
• Imugene Limited
• Jiangsu Hengrui Medicine Co.
• Merck & Co., Inc.
• Novartis AG
• OBI Pharma, Inc.
• Pfizer Inc.
• Samsung Bioepis Co., Ltd.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Impact of Covid-19 and a Looming Global Recession
  • Gastric Cancer - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Increasing Incidence of Gastric Cancer Globally Drives Demand for Early Detection and Treatment Solutions
  • Here's the Story: How Advancements in Diagnostic Technologies Are Shaping the Early Diagnosis of Gastric Cancer
  • Rising Awareness of Lifestyle Factors and Their Impact on Gastric Cancer Rates Fuels Preventative Healthcare Initiatives
  • Surge in Research and Development Investment Accelerates Progress in Targeted Therapies for Gastric Cancer
  • Growing Focus on Immunotherapy and Precision Medicine Expands Treatment Options for Gastric Cancer Patients
  • Here's How Advancements in Biomarker Identification are Enhancing Personalized Treatment Approaches
  • Increasing Adoption of Minimally Invasive Surgery Techniques Strengthens the Business Case for Advanced Gastric Cancer Treatments
  • Rising Demand for Multidisciplinary Cancer Care Models Drives the Integration of Gastric Cancer Treatment Solutions
  • Expanding Access to Healthcare and Screening Programs in Developing Markets Boosts Early Detection Rates
  • Technological Advancements in Endoscopic Screening and Imaging Techniques Propel Market Growth
  • Rising Use of Artificial Intelligence and Machine Learning in Gastric Cancer Diagnosis and Prognosis Enhances Treatment Strategies
  • Advancements in Palliative Care for Gastric Cancer Patients Expand Treatment Options and Improve Quality of Life
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Gastric Cancer Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Gastric Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Gastric Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Gastric Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Adenocarcinoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Adenocarcinoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Adenocarcinoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Lymphoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Lymphoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Lymphoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Gastrointestinal Stromal Tumor by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Gastrointestinal Stromal Tumor by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Gastrointestinal Stromal Tumor by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Carcinoid Tumor by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Carcinoid Tumor by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Carcinoid Tumor by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Other Disease Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for PD-1 / PD-L1 Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for PD-1 / PD-L1 Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for PD-1 / PD-L1 Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for HER2 Antagonists by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for HER2 Antagonists by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for HER2 Antagonists by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for VEGFR2 Antagonists by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for VEGFR2 Antagonists by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for VEGFR2 Antagonists by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Injectable by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Injectable by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 37: World 15-Year Perspective for Injectable by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 38: World Recent Past, Current & Future Analysis for Specialty & Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 39: World Historic Review for Specialty & Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 40: World 15-Year Perspective for Specialty & Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 41: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 42: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 43: World 15-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 44: World Recent Past, Current & Future Analysis for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 45: World Historic Review for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 46: World 15-Year Perspective for Other Distribution Channels by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 47: World Recent Past, Current & Future Analysis for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 48: World Historic Review for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 49: World 15-Year Perspective for Immunotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 50: World Recent Past, Current & Future Analysis for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 51: World Historic Review for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 52: World 15-Year Perspective for Targeted Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 53: World Recent Past, Current & Future Analysis for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 54: World Historic Review for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 55: World 15-Year Perspective for Chemotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 56: World Recent Past, Current & Future Analysis for Radiation Therapy & Surgery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 57: World Historic Review for Radiation Therapy & Surgery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 58: World 15-Year Perspective for Radiation Therapy & Surgery by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Gastric Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 59: USA Recent Past, Current & Future Analysis for Gastric Cancer by Disease Type - Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: USA Historic Review for Gastric Cancer by Disease Type - Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 61: USA 15-Year Perspective for Gastric Cancer by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor and Other Disease Types for the Years 2015, 2025 & 2030
  • TABLE 62: USA Recent Past, Current & Future Analysis for Gastric Cancer by Drug Class - PD-1 / PD-L1 Inhibitors, HER2 Antagonists, VEGFR2 Antagonists and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: USA Historic Review for Gastric Cancer by Drug Class - PD-1 / PD-L1 Inhibitors, HER2 Antagonists, VEGFR2 Antagonists and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 64: USA 15-Year Perspective for Gastric Cancer by Drug Class - Percentage Breakdown of Value Sales for PD-1 / PD-L1 Inhibitors, HER2 Antagonists, VEGFR2 Antagonists and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 65: USA Recent Past, Current & Future Analysis for Gastric Cancer by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: USA Historic Review for Gastric Cancer by Administration Route - Oral and Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 67: USA 15-Year Perspective for Gastric Cancer by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2015, 2025 & 2030
  • TABLE 68: USA Recent Past, Current & Future Analysis for Gastric Cancer by Distribution Channel - Specialty & Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: USA Historic Review for Gastric Cancer by Distribution Channel - Specialty & Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 70: USA 15-Year Perspective for Gastric Cancer by Distribution Channel - Percentage Breakdown of Value Sales for Specialty & Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • TABLE 71: USA Recent Past, Current & Future Analysis for Gastric Cancer by Treatment Type - Immunotherapy, Targeted Therapy, Chemotherapy and Radiation Therapy & Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: USA Historic Review for Gastric Cancer by Treatment Type - Immunotherapy, Targeted Therapy, Chemotherapy and Radiation Therapy & Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 73: USA 15-Year Perspective for Gastric Cancer by Treatment Type - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Chemotherapy and Radiation Therapy & Surgery for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 74: Canada Recent Past, Current & Future Analysis for Gastric Cancer by Disease Type - Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Canada Historic Review for Gastric Cancer by Disease Type - Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 76: Canada 15-Year Perspective for Gastric Cancer by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor and Other Disease Types for the Years 2015, 2025 & 2030
  • TABLE 77: Canada Recent Past, Current & Future Analysis for Gastric Cancer by Drug Class - PD-1 / PD-L1 Inhibitors, HER2 Antagonists, VEGFR2 Antagonists and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Canada Historic Review for Gastric Cancer by Drug Class - PD-1 / PD-L1 Inhibitors, HER2 Antagonists, VEGFR2 Antagonists and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 79: Canada 15-Year Perspective for Gastric Cancer by Drug Class - Percentage Breakdown of Value Sales for PD-1 / PD-L1 Inhibitors, HER2 Antagonists, VEGFR2 Antagonists and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 80: Canada Recent Past, Current & Future Analysis for Gastric Cancer by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Canada Historic Review for Gastric Cancer by Administration Route - Oral and Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 82: Canada 15-Year Perspective for Gastric Cancer by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2015, 2025 & 2030
  • TABLE 83: Canada Recent Past, Current & Future Analysis for Gastric Cancer by Distribution Channel - Specialty & Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Canada Historic Review for Gastric Cancer by Distribution Channel - Specialty & Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 85: Canada 15-Year Perspective for Gastric Cancer by Distribution Channel - Percentage Breakdown of Value Sales for Specialty & Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • TABLE 86: Canada Recent Past, Current & Future Analysis for Gastric Cancer by Treatment Type - Immunotherapy, Targeted Therapy, Chemotherapy and Radiation Therapy & Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Canada Historic Review for Gastric Cancer by Treatment Type - Immunotherapy, Targeted Therapy, Chemotherapy and Radiation Therapy & Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 88: Canada 15-Year Perspective for Gastric Cancer by Treatment Type - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Chemotherapy and Radiation Therapy & Surgery for the Years 2015, 2025 & 2030
• JAPAN
  • Gastric Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 89: Japan Recent Past, Current & Future Analysis for Gastric Cancer by Disease Type - Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: Japan Historic Review for Gastric Cancer by Disease Type - Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 91: Japan 15-Year Perspective for Gastric Cancer by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor and Other Disease Types for the Years 2015, 2025 & 2030
  • TABLE 92: Japan Recent Past, Current & Future Analysis for Gastric Cancer by Drug Class - PD-1 / PD-L1 Inhibitors, HER2 Antagonists, VEGFR2 Antagonists and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Japan Historic Review for Gastric Cancer by Drug Class - PD-1 / PD-L1 Inhibitors, HER2 Antagonists, VEGFR2 Antagonists and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 94: Japan 15-Year Perspective for Gastric Cancer by Drug Class - Percentage Breakdown of Value Sales for PD-1 / PD-L1 Inhibitors, HER2 Antagonists, VEGFR2 Antagonists and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 95: Japan Recent Past, Current & Future Analysis for Gastric Cancer by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Japan Historic Review for Gastric Cancer by Administration Route - Oral and Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 97: Japan 15-Year Perspective for Gastric Cancer by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2015, 2025 & 2030
  • TABLE 98: Japan Recent Past, Current & Future Analysis for Gastric Cancer by Distribution Channel - Specialty & Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Japan Historic Review for Gastric Cancer by Distribution Channel - Specialty & Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 100: Japan 15-Year Perspective for Gastric Cancer by Distribution Channel - Percentage Breakdown of Value Sales for Specialty & Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • TABLE 101: Japan Recent Past, Current & Future Analysis for Gastric Cancer by Treatment Type - Immunotherapy, Targeted Therapy, Chemotherapy and Radiation Therapy & Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Japan Historic Review for Gastric Cancer by Treatment Type - Immunotherapy, Targeted Therapy, Chemotherapy and Radiation Therapy & Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 103: Japan 15-Year Perspective for Gastric Cancer by Treatment Type - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Chemotherapy and Radiation Therapy & Surgery for the Years 2015, 2025 & 2030
• CHINA
  • Gastric Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 104: China Recent Past, Current & Future Analysis for Gastric Cancer by Disease Type - Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: China Historic Review for Gastric Cancer by Disease Type - Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 106: China 15-Year Perspective for Gastric Cancer by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor and Other Disease Types for the Years 2015, 2025 & 2030
  • TABLE 107: China Recent Past, Current & Future Analysis for Gastric Cancer by Drug Class - PD-1 / PD-L1 Inhibitors, HER2 Antagonists, VEGFR2 Antagonists and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: China Historic Review for Gastric Cancer by Drug Class - PD-1 / PD-L1 Inhibitors, HER2 Antagonists, VEGFR2 Antagonists and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 109: China 15-Year Perspective for Gastric Cancer by Drug Class - Percentage Breakdown of Value Sales for PD-1 / PD-L1 Inhibitors, HER2 Antagonists, VEGFR2 Antagonists and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 110: China Recent Past, Current & Future Analysis for Gastric Cancer by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: China Historic Review for Gastric Cancer by Administration Route - Oral and Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 112: China 15-Year Perspective for Gastric Cancer by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2015, 2025 & 2030
  • TABLE 113: China Recent Past, Current & Future Analysis for Gastric Cancer by Distribution Channel - Specialty & Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: China Historic Review for Gastric Cancer by Distribution Channel - Specialty & Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 115: China 15-Year Perspective for Gastric Cancer by Distribution Channel - Percentage Breakdown of Value Sales for Specialty & Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • TABLE 116: China Recent Past, Current & Future Analysis for Gastric Cancer by Treatment Type - Immunotherapy, Targeted Therapy, Chemotherapy and Radiation Therapy & Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: China Historic Review for Gastric Cancer by Treatment Type - Immunotherapy, Targeted Therapy, Chemotherapy and Radiation Therapy & Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 118: China 15-Year Perspective for Gastric Cancer by Treatment Type - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Chemotherapy and Radiation Therapy & Surgery for the Years 2015, 2025 & 2030
• EUROPE
  • Gastric Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 119: Europe Recent Past, Current & Future Analysis for Gastric Cancer by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 120: Europe Historic Review for Gastric Cancer by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 121: Europe 15-Year Perspective for Gastric Cancer by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 122: Europe Recent Past, Current & Future Analysis for Gastric Cancer by Disease Type - Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Europe Historic Review for Gastric Cancer by Disease Type - Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 124: Europe 15-Year Perspective for Gastric Cancer by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor and Other Disease Types for the Years 2015, 2025 & 2030
  • TABLE 125: Europe Recent Past, Current & Future Analysis for Gastric Cancer by Drug Class - PD-1 / PD-L1 Inhibitors, HER2 Antagonists, VEGFR2 Antagonists and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Europe Historic Review for Gastric Cancer by Drug Class - PD-1 / PD-L1 Inhibitors, HER2 Antagonists, VEGFR2 Antagonists and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 127: Europe 15-Year Perspective for Gastric Cancer by Drug Class - Percentage Breakdown of Value Sales for PD-1 / PD-L1 Inhibitors, HER2 Antagonists, VEGFR2 Antagonists and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 128: Europe Recent Past, Current & Future Analysis for Gastric Cancer by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Europe Historic Review for Gastric Cancer by Administration Route - Oral and Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 130: Europe 15-Year Perspective for Gastric Cancer by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2015, 2025 & 2030
  • TABLE 131: Europe Recent Past, Current & Future Analysis for Gastric Cancer by Distribution Channel - Specialty & Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Europe Historic Review for Gastric Cancer by Distribution Channel - Specialty & Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 133: Europe 15-Year Perspective for Gastric Cancer by Distribution Channel - Percentage Breakdown of Value Sales for Specialty & Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • TABLE 134: Europe Recent Past, Current & Future Analysis for Gastric Cancer by Treatment Type - Immunotherapy, Targeted Therapy, Chemotherapy and Radiation Therapy & Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Europe Historic Review for Gastric Cancer by Treatment Type - Immunotherapy, Targeted Therapy, Chemotherapy and Radiation Therapy & Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 136: Europe 15-Year Perspective for Gastric Cancer by Treatment Type - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Chemotherapy and Radiation Therapy & Surgery for the Years 2015, 2025 & 2030
• FRANCE
  • Gastric Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 137: France Recent Past, Current & Future Analysis for Gastric Cancer by Disease Type - Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: France Historic Review for Gastric Cancer by Disease Type - Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 139: France 15-Year Perspective for Gastric Cancer by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor and Other Disease Types for the Years 2015, 2025 & 2030
  • TABLE 140: France Recent Past, Current & Future Analysis for Gastric Cancer by Drug Class - PD-1 / PD-L1 Inhibitors, HER2 Antagonists, VEGFR2 Antagonists and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: France Historic Review for Gastric Cancer by Drug Class - PD-1 / PD-L1 Inhibitors, HER2 Antagonists, VEGFR2 Antagonists and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 142: France 15-Year Perspective for Gastric Cancer by Drug Class - Percentage Breakdown of Value Sales for PD-1 / PD-L1 Inhibitors, HER2 Antagonists, VEGFR2 Antagonists and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 143: France Recent Past, Current & Future Analysis for Gastric Cancer by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: France Historic Review for Gastric Cancer by Administration Route - Oral and Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 145: France 15-Year Perspective for Gastric Cancer by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2015, 2025 & 2030
  • TABLE 146: France Recent Past, Current & Future Analysis for Gastric Cancer by Distribution Channel - Specialty & Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: France Historic Review for Gastric Cancer by Distribution Channel - Specialty & Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 148: France 15-Year Perspective for Gastric Cancer by Distribution Channel - Percentage Breakdown of Value Sales for Specialty & Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • TABLE 149: France Recent Past, Current & Future Analysis for Gastric Cancer by Treatment Type - Immunotherapy, Targeted Therapy, Chemotherapy and Radiation Therapy & Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 150: France Historic Review for Gastric Cancer by Treatment Type - Immunotherapy, Targeted Therapy, Chemotherapy and Radiation Therapy & Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 151: France 15-Year Perspective for Gastric Cancer by Treatment Type - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Chemotherapy and Radiation Therapy & Surgery for the Years 2015, 2025 & 2030
• GERMANY
  • Gastric Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 152: Germany Recent Past, Current & Future Analysis for Gastric Cancer by Disease Type - Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Germany Historic Review for Gastric Cancer by Disease Type - Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 154: Germany 15-Year Perspective for Gastric Cancer by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor and Other Disease Types for the Years 2015, 2025 & 2030
  • TABLE 155: Germany Recent Past, Current & Future Analysis for Gastric Cancer by Drug Class - PD-1 / PD-L1 Inhibitors, HER2 Antagonists, VEGFR2 Antagonists and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Germany Historic Review for Gastric Cancer by Drug Class - PD-1 / PD-L1 Inhibitors, HER2 Antagonists, VEGFR2 Antagonists and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 157: Germany 15-Year Perspective for Gastric Cancer by Drug Class - Percentage Breakdown of Value Sales for PD-1 / PD-L1 Inhibitors, HER2 Antagonists, VEGFR2 Antagonists and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 158: Germany Recent Past, Current & Future Analysis for Gastric Cancer by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Germany Historic Review for Gastric Cancer by Administration Route - Oral and Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 160: Germany 15-Year Perspective for Gastric Cancer by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2015, 2025 & 2030
  • TABLE 161: Germany Recent Past, Current & Future Analysis for Gastric Cancer by Distribution Channel - Specialty & Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Germany Historic Review for Gastric Cancer by Distribution Channel - Specialty & Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 163: Germany 15-Year Perspective for Gastric Cancer by Distribution Channel - Percentage Breakdown of Value Sales for Specialty & Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • TABLE 164: Germany Recent Past, Current & Future Analysis for Gastric Cancer by Treatment Type - Immunotherapy, Targeted Therapy, Chemotherapy and Radiation Therapy & Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Germany Historic Review for Gastric Cancer by Treatment Type - Immunotherapy, Targeted Therapy, Chemotherapy and Radiation Therapy & Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 166: Germany 15-Year Perspective for Gastric Cancer by Treatment Type - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Chemotherapy and Radiation Therapy & Surgery for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 167: Italy Recent Past, Current & Future Analysis for Gastric Cancer by Disease Type - Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Italy Historic Review for Gastric Cancer by Disease Type - Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 169: Italy 15-Year Perspective for Gastric Cancer by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor and Other Disease Types for the Years 2015, 2025 & 2030
  • TABLE 170: Italy Recent Past, Current & Future Analysis for Gastric Cancer by Drug Class - PD-1 / PD-L1 Inhibitors, HER2 Antagonists, VEGFR2 Antagonists and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Italy Historic Review for Gastric Cancer by Drug Class - PD-1 / PD-L1 Inhibitors, HER2 Antagonists, VEGFR2 Antagonists and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 172: Italy 15-Year Perspective for Gastric Cancer by Drug Class - Percentage Breakdown of Value Sales for PD-1 / PD-L1 Inhibitors, HER2 Antagonists, VEGFR2 Antagonists and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 173: Italy Recent Past, Current & Future Analysis for Gastric Cancer by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: Italy Historic Review for Gastric Cancer by Administration Route - Oral and Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 175: Italy 15-Year Perspective for Gastric Cancer by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2015, 2025 & 2030
  • TABLE 176: Italy Recent Past, Current & Future Analysis for Gastric Cancer by Distribution Channel - Specialty & Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: Italy Historic Review for Gastric Cancer by Distribution Channel - Specialty & Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 178: Italy 15-Year Perspective for Gastric Cancer by Distribution Channel - Percentage Breakdown of Value Sales for Specialty & Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • TABLE 179: Italy Recent Past, Current & Future Analysis for Gastric Cancer by Treatment Type - Immunotherapy, Targeted Therapy, Chemotherapy and Radiation Therapy & Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: Italy Historic Review for Gastric Cancer by Treatment Type - Immunotherapy, Targeted Therapy, Chemotherapy and Radiation Therapy & Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 181: Italy 15-Year Perspective for Gastric Cancer by Treatment Type - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Chemotherapy and Radiation Therapy & Surgery for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Gastric Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 182: UK Recent Past, Current & Future Analysis for Gastric Cancer by Disease Type - Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: UK Historic Review for Gastric Cancer by Disease Type - Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 184: UK 15-Year Perspective for Gastric Cancer by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor and Other Disease Types for the Years 2015, 2025 & 2030
  • TABLE 185: UK Recent Past, Current & Future Analysis for Gastric Cancer by Drug Class - PD-1 / PD-L1 Inhibitors, HER2 Antagonists, VEGFR2 Antagonists and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: UK Historic Review for Gastric Cancer by Drug Class - PD-1 / PD-L1 Inhibitors, HER2 Antagonists, VEGFR2 Antagonists and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 187: UK 15-Year Perspective for Gastric Cancer by Drug Class - Percentage Breakdown of Value Sales for PD-1 / PD-L1 Inhibitors, HER2 Antagonists, VEGFR2 Antagonists and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 188: UK Recent Past, Current & Future Analysis for Gastric Cancer by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: UK Historic Review for Gastric Cancer by Administration Route - Oral and Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 190: UK 15-Year Perspective for Gastric Cancer by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2015, 2025 & 2030
  • TABLE 191: UK Recent Past, Current & Future Analysis for Gastric Cancer by Distribution Channel - Specialty & Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: UK Historic Review for Gastric Cancer by Distribution Channel - Specialty & Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 193: UK 15-Year Perspective for Gastric Cancer by Distribution Channel - Percentage Breakdown of Value Sales for Specialty & Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • TABLE 194: UK Recent Past, Current & Future Analysis for Gastric Cancer by Treatment Type - Immunotherapy, Targeted Therapy, Chemotherapy and Radiation Therapy & Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: UK Historic Review for Gastric Cancer by Treatment Type - Immunotherapy, Targeted Therapy, Chemotherapy and Radiation Therapy & Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 196: UK 15-Year Perspective for Gastric Cancer by Treatment Type - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Chemotherapy and Radiation Therapy & Surgery for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 197: Spain Recent Past, Current & Future Analysis for Gastric Cancer by Disease Type - Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Spain Historic Review for Gastric Cancer by Disease Type - Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 199: Spain 15-Year Perspective for Gastric Cancer by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor and Other Disease Types for the Years 2015, 2025 & 2030
  • TABLE 200: Spain Recent Past, Current & Future Analysis for Gastric Cancer by Drug Class - PD-1 / PD-L1 Inhibitors, HER2 Antagonists, VEGFR2 Antagonists and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Spain Historic Review for Gastric Cancer by Drug Class - PD-1 / PD-L1 Inhibitors, HER2 Antagonists, VEGFR2 Antagonists and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 202: Spain 15-Year Perspective for Gastric Cancer by Drug Class - Percentage Breakdown of Value Sales for PD-1 / PD-L1 Inhibitors, HER2 Antagonists, VEGFR2 Antagonists and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 203: Spain Recent Past, Current & Future Analysis for Gastric Cancer by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Spain Historic Review for Gastric Cancer by Administration Route - Oral and Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 205: Spain 15-Year Perspective for Gastric Cancer by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2015, 2025 & 2030
  • TABLE 206: Spain Recent Past, Current & Future Analysis for Gastric Cancer by Distribution Channel - Specialty & Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Spain Historic Review for Gastric Cancer by Distribution Channel - Specialty & Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 208: Spain 15-Year Perspective for Gastric Cancer by Distribution Channel - Percentage Breakdown of Value Sales for Specialty & Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • TABLE 209: Spain Recent Past, Current & Future Analysis for Gastric Cancer by Treatment Type - Immunotherapy, Targeted Therapy, Chemotherapy and Radiation Therapy & Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Spain Historic Review for Gastric Cancer by Treatment Type - Immunotherapy, Targeted Therapy, Chemotherapy and Radiation Therapy & Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 211: Spain 15-Year Perspective for Gastric Cancer by Treatment Type - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Chemotherapy and Radiation Therapy & Surgery for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 212: Russia Recent Past, Current & Future Analysis for Gastric Cancer by Disease Type - Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Russia Historic Review for Gastric Cancer by Disease Type - Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 214: Russia 15-Year Perspective for Gastric Cancer by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor and Other Disease Types for the Years 2015, 2025 & 2030
  • TABLE 215: Russia Recent Past, Current & Future Analysis for Gastric Cancer by Drug Class - PD-1 / PD-L1 Inhibitors, HER2 Antagonists, VEGFR2 Antagonists and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Russia Historic Review for Gastric Cancer by Drug Class - PD-1 / PD-L1 Inhibitors, HER2 Antagonists, VEGFR2 Antagonists and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 217: Russia 15-Year Perspective for Gastric Cancer by Drug Class - Percentage Breakdown of Value Sales for PD-1 / PD-L1 Inhibitors, HER2 Antagonists, VEGFR2 Antagonists and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 218: Russia Recent Past, Current & Future Analysis for Gastric Cancer by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Russia Historic Review for Gastric Cancer by Administration Route - Oral and Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 220: Russia 15-Year Perspective for Gastric Cancer by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2015, 2025 & 2030
  • TABLE 221: Russia Recent Past, Current & Future Analysis for Gastric Cancer by Distribution Channel - Specialty & Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Russia Historic Review for Gastric Cancer by Distribution Channel - Specialty & Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 223: Russia 15-Year Perspective for Gastric Cancer by Distribution Channel - Percentage Breakdown of Value Sales for Specialty & Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • TABLE 224: Russia Recent Past, Current & Future Analysis for Gastric Cancer by Treatment Type - Immunotherapy, Targeted Therapy, Chemotherapy and Radiation Therapy & Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Russia Historic Review for Gastric Cancer by Treatment Type - Immunotherapy, Targeted Therapy, Chemotherapy and Radiation Therapy & Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 226: Russia 15-Year Perspective for Gastric Cancer by Treatment Type - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Chemotherapy and Radiation Therapy & Surgery for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 227: Rest of Europe Recent Past, Current & Future Analysis for Gastric Cancer by Disease Type - Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Rest of Europe Historic Review for Gastric Cancer by Disease Type - Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 229: Rest of Europe 15-Year Perspective for Gastric Cancer by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor and Other Disease Types for the Years 2015, 2025 & 2030
  • TABLE 230: Rest of Europe Recent Past, Current & Future Analysis for Gastric Cancer by Drug Class - PD-1 / PD-L1 Inhibitors, HER2 Antagonists, VEGFR2 Antagonists and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Rest of Europe Historic Review for Gastric Cancer by Drug Class - PD-1 / PD-L1 Inhibitors, HER2 Antagonists, VEGFR2 Antagonists and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 232: Rest of Europe 15-Year Perspective for Gastric Cancer by Drug Class - Percentage Breakdown of Value Sales for PD-1 / PD-L1 Inhibitors, HER2 Antagonists, VEGFR2 Antagonists and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 233: Rest of Europe Recent Past, Current & Future Analysis for Gastric Cancer by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Rest of Europe Historic Review for Gastric Cancer by Administration Route - Oral and Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 235: Rest of Europe 15-Year Perspective for Gastric Cancer by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2015, 2025 & 2030
  • TABLE 236: Rest of Europe Recent Past, Current & Future Analysis for Gastric Cancer by Distribution Channel - Specialty & Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Rest of Europe Historic Review for Gastric Cancer by Distribution Channel - Specialty & Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 238: Rest of Europe 15-Year Perspective for Gastric Cancer by Distribution Channel - Percentage Breakdown of Value Sales for Specialty & Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • TABLE 239: Rest of Europe Recent Past, Current & Future Analysis for Gastric Cancer by Treatment Type - Immunotherapy, Targeted Therapy, Chemotherapy and Radiation Therapy & Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Rest of Europe Historic Review for Gastric Cancer by Treatment Type - Immunotherapy, Targeted Therapy, Chemotherapy and Radiation Therapy & Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 241: Rest of Europe 15-Year Perspective for Gastric Cancer by Treatment Type - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Chemotherapy and Radiation Therapy & Surgery for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Gastric Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 242: Asia-Pacific Recent Past, Current & Future Analysis for Gastric Cancer by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 243: Asia-Pacific Historic Review for Gastric Cancer by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 244: Asia-Pacific 15-Year Perspective for Gastric Cancer by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 245: Asia-Pacific Recent Past, Current & Future Analysis for Gastric Cancer by Disease Type - Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Asia-Pacific Historic Review for Gastric Cancer by Disease Type - Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 247: Asia-Pacific 15-Year Perspective for Gastric Cancer by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor and Other Disease Types for the Years 2015, 2025 & 2030
  • TABLE 248: Asia-Pacific Recent Past, Current & Future Analysis for Gastric Cancer by Drug Class - PD-1 / PD-L1 Inhibitors, HER2 Antagonists, VEGFR2 Antagonists and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Asia-Pacific Historic Review for Gastric Cancer by Drug Class - PD-1 / PD-L1 Inhibitors, HER2 Antagonists, VEGFR2 Antagonists and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 250: Asia-Pacific 15-Year Perspective for Gastric Cancer by Drug Class - Percentage Breakdown of Value Sales for PD-1 / PD-L1 Inhibitors, HER2 Antagonists, VEGFR2 Antagonists and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 251: Asia-Pacific Recent Past, Current & Future Analysis for Gastric Cancer by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Asia-Pacific Historic Review for Gastric Cancer by Administration Route - Oral and Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 253: Asia-Pacific 15-Year Perspective for Gastric Cancer by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2015, 2025 & 2030
  • TABLE 254: Asia-Pacific Recent Past, Current & Future Analysis for Gastric Cancer by Distribution Channel - Specialty & Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Asia-Pacific Historic Review for Gastric Cancer by Distribution Channel - Specialty & Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 256: Asia-Pacific 15-Year Perspective for Gastric Cancer by Distribution Channel - Percentage Breakdown of Value Sales for Specialty & Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • TABLE 257: Asia-Pacific Recent Past, Current & Future Analysis for Gastric Cancer by Treatment Type - Immunotherapy, Targeted Therapy, Chemotherapy and Radiation Therapy & Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Asia-Pacific Historic Review for Gastric Cancer by Treatment Type - Immunotherapy, Targeted Therapy, Chemotherapy and Radiation Therapy & Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 259: Asia-Pacific 15-Year Perspective for Gastric Cancer by Treatment Type - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Chemotherapy and Radiation Therapy & Surgery for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Gastric Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 260: Australia Recent Past, Current & Future Analysis for Gastric Cancer by Disease Type - Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Australia Historic Review for Gastric Cancer by Disease Type - Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 262: Australia 15-Year Perspective for Gastric Cancer by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor and Other Disease Types for the Years 2015, 2025 & 2030
  • TABLE 263: Australia Recent Past, Current & Future Analysis for Gastric Cancer by Drug Class - PD-1 / PD-L1 Inhibitors, HER2 Antagonists, VEGFR2 Antagonists and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Australia Historic Review for Gastric Cancer by Drug Class - PD-1 / PD-L1 Inhibitors, HER2 Antagonists, VEGFR2 Antagonists and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 265: Australia 15-Year Perspective for Gastric Cancer by Drug Class - Percentage Breakdown of Value Sales for PD-1 / PD-L1 Inhibitors, HER2 Antagonists, VEGFR2 Antagonists and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 266: Australia Recent Past, Current & Future Analysis for Gastric Cancer by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Australia Historic Review for Gastric Cancer by Administration Route - Oral and Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 268: Australia 15-Year Perspective for Gastric Cancer by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2015, 2025 & 2030
  • TABLE 269: Australia Recent Past, Current & Future Analysis for Gastric Cancer by Distribution Channel - Specialty & Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Australia Historic Review for Gastric Cancer by Distribution Channel - Specialty & Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 271: Australia 15-Year Perspective for Gastric Cancer by Distribution Channel - Percentage Breakdown of Value Sales for Specialty & Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • TABLE 272: Australia Recent Past, Current & Future Analysis for Gastric Cancer by Treatment Type - Immunotherapy, Targeted Therapy, Chemotherapy and Radiation Therapy & Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Australia Historic Review for Gastric Cancer by Treatment Type - Immunotherapy, Targeted Therapy, Chemotherapy and Radiation Therapy & Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 274: Australia 15-Year Perspective for Gastric Cancer by Treatment Type - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Chemotherapy and Radiation Therapy & Surgery for the Years 2015, 2025 & 2030
• INDIA
  • Gastric Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 275: India Recent Past, Current & Future Analysis for Gastric Cancer by Disease Type - Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 276: India Historic Review for Gastric Cancer by Disease Type - Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 277: India 15-Year Perspective for Gastric Cancer by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor and Other Disease Types for the Years 2015, 2025 & 2030
  • TABLE 278: India Recent Past, Current & Future Analysis for Gastric Cancer by Drug Class - PD-1 / PD-L1 Inhibitors, HER2 Antagonists, VEGFR2 Antagonists and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 279: India Historic Review for Gastric Cancer by Drug Class - PD-1 / PD-L1 Inhibitors, HER2 Antagonists, VEGFR2 Antagonists and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 280: India 15-Year Perspective for Gastric Cancer by Drug Class - Percentage Breakdown of Value Sales for PD-1 / PD-L1 Inhibitors, HER2 Antagonists, VEGFR2 Antagonists and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 281: India Recent Past, Current & Future Analysis for Gastric Cancer by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 282: India Historic Review for Gastric Cancer by Administration Route - Oral and Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 283: India 15-Year Perspective for Gastric Cancer by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2015, 2025 & 2030
  • TABLE 284: India Recent Past, Current & Future Analysis for Gastric Cancer by Distribution Channel - Specialty & Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 285: India Historic Review for Gastric Cancer by Distribution Channel - Specialty & Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 286: India 15-Year Perspective for Gastric Cancer by Distribution Channel - Percentage Breakdown of Value Sales for Specialty & Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • TABLE 287: India Recent Past, Current & Future Analysis for Gastric Cancer by Treatment Type - Immunotherapy, Targeted Therapy, Chemotherapy and Radiation Therapy & Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 288: India Historic Review for Gastric Cancer by Treatment Type - Immunotherapy, Targeted Therapy, Chemotherapy and Radiation Therapy & Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 289: India 15-Year Perspective for Gastric Cancer by Treatment Type - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Chemotherapy and Radiation Therapy & Surgery for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 290: South Korea Recent Past, Current & Future Analysis for Gastric Cancer by Disease Type - Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 291: South Korea Historic Review for Gastric Cancer by Disease Type - Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 292: South Korea 15-Year Perspective for Gastric Cancer by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor and Other Disease Types for the Years 2015, 2025 & 2030
  • TABLE 293: South Korea Recent Past, Current & Future Analysis for Gastric Cancer by Drug Class - PD-1 / PD-L1 Inhibitors, HER2 Antagonists, VEGFR2 Antagonists and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 294: South Korea Historic Review for Gastric Cancer by Drug Class - PD-1 / PD-L1 Inhibitors, HER2 Antagonists, VEGFR2 Antagonists and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 295: South Korea 15-Year Perspective for Gastric Cancer by Drug Class - Percentage Breakdown of Value Sales for PD-1 / PD-L1 Inhibitors, HER2 Antagonists, VEGFR2 Antagonists and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 296: South Korea Recent Past, Current & Future Analysis for Gastric Cancer by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 297: South Korea Historic Review for Gastric Cancer by Administration Route - Oral and Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 298: South Korea 15-Year Perspective for Gastric Cancer by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2015, 2025 & 2030
  • TABLE 299: South Korea Recent Past, Current & Future Analysis for Gastric Cancer by Distribution Channel - Specialty & Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 300: South Korea Historic Review for Gastric Cancer by Distribution Channel - Specialty & Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 301: South Korea 15-Year Perspective for Gastric Cancer by Distribution Channel - Percentage Breakdown of Value Sales for Specialty & Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • TABLE 302: South Korea Recent Past, Current & Future Analysis for Gastric Cancer by Treatment Type - Immunotherapy, Targeted Therapy, Chemotherapy and Radiation Therapy & Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 303: South Korea Historic Review for Gastric Cancer by Treatment Type - Immunotherapy, Targeted Therapy, Chemotherapy and Radiation Therapy & Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 304: South Korea 15-Year Perspective for Gastric Cancer by Treatment Type - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Chemotherapy and Radiation Therapy & Surgery for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 305: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Gastric Cancer by Disease Type - Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Rest of Asia-Pacific Historic Review for Gastric Cancer by Disease Type - Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 307: Rest of Asia-Pacific 15-Year Perspective for Gastric Cancer by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor and Other Disease Types for the Years 2015, 2025 & 2030
  • TABLE 308: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Gastric Cancer by Drug Class - PD-1 / PD-L1 Inhibitors, HER2 Antagonists, VEGFR2 Antagonists and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Rest of Asia-Pacific Historic Review for Gastric Cancer by Drug Class - PD-1 / PD-L1 Inhibitors, HER2 Antagonists, VEGFR2 Antagonists and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 310: Rest of Asia-Pacific 15-Year Perspective for Gastric Cancer by Drug Class - Percentage Breakdown of Value Sales for PD-1 / PD-L1 Inhibitors, HER2 Antagonists, VEGFR2 Antagonists and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 311: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Gastric Cancer by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 312: Rest of Asia-Pacific Historic Review for Gastric Cancer by Administration Route - Oral and Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 313: Rest of Asia-Pacific 15-Year Perspective for Gastric Cancer by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2015, 2025 & 2030
  • TABLE 314: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Gastric Cancer by Distribution Channel - Specialty & Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 315: Rest of Asia-Pacific Historic Review for Gastric Cancer by Distribution Channel - Specialty & Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 316: Rest of Asia-Pacific 15-Year Perspective for Gastric Cancer by Distribution Channel - Percentage Breakdown of Value Sales for Specialty & Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • TABLE 317: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Gastric Cancer by Treatment Type - Immunotherapy, Targeted Therapy, Chemotherapy and Radiation Therapy & Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 318: Rest of Asia-Pacific Historic Review for Gastric Cancer by Treatment Type - Immunotherapy, Targeted Therapy, Chemotherapy and Radiation Therapy & Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 319: Rest of Asia-Pacific 15-Year Perspective for Gastric Cancer by Treatment Type - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Chemotherapy and Radiation Therapy & Surgery for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Gastric Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 320: Latin America Recent Past, Current & Future Analysis for Gastric Cancer by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 321: Latin America Historic Review for Gastric Cancer by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 322: Latin America 15-Year Perspective for Gastric Cancer by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 323: Latin America Recent Past, Current & Future Analysis for Gastric Cancer by Disease Type - Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 324: Latin America Historic Review for Gastric Cancer by Disease Type - Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 325: Latin America 15-Year Perspective for Gastric Cancer by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor and Other Disease Types for the Years 2015, 2025 & 2030
  • TABLE 326: Latin America Recent Past, Current & Future Analysis for Gastric Cancer by Drug Class - PD-1 / PD-L1 Inhibitors, HER2 Antagonists, VEGFR2 Antagonists and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 327: Latin America Historic Review for Gastric Cancer by Drug Class - PD-1 / PD-L1 Inhibitors, HER2 Antagonists, VEGFR2 Antagonists and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 328: Latin America 15-Year Perspective for Gastric Cancer by Drug Class - Percentage Breakdown of Value Sales for PD-1 / PD-L1 Inhibitors, HER2 Antagonists, VEGFR2 Antagonists and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 329: Latin America Recent Past, Current & Future Analysis for Gastric Cancer by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 330: Latin America Historic Review for Gastric Cancer by Administration Route - Oral and Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 331: Latin America 15-Year Perspective for Gastric Cancer by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2015, 2025 & 2030
  • TABLE 332: Latin America Recent Past, Current & Future Analysis for Gastric Cancer by Distribution Channel - Specialty & Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 333: Latin America Historic Review for Gastric Cancer by Distribution Channel - Specialty & Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 334: Latin America 15-Year Perspective for Gastric Cancer by Distribution Channel - Percentage Breakdown of Value Sales for Specialty & Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • TABLE 335: Latin America Recent Past, Current & Future Analysis for Gastric Cancer by Treatment Type - Immunotherapy, Targeted Therapy, Chemotherapy and Radiation Therapy & Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 336: Latin America Historic Review for Gastric Cancer by Treatment Type - Immunotherapy, Targeted Therapy, Chemotherapy and Radiation Therapy & Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 337: Latin America 15-Year Perspective for Gastric Cancer by Treatment Type - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Chemotherapy and Radiation Therapy & Surgery for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 338: Argentina Recent Past, Current & Future Analysis for Gastric Cancer by Disease Type - Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 339: Argentina Historic Review for Gastric Cancer by Disease Type - Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 340: Argentina 15-Year Perspective for Gastric Cancer by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor and Other Disease Types for the Years 2015, 2025 & 2030
  • TABLE 341: Argentina Recent Past, Current & Future Analysis for Gastric Cancer by Drug Class - PD-1 / PD-L1 Inhibitors, HER2 Antagonists, VEGFR2 Antagonists and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 342: Argentina Historic Review for Gastric Cancer by Drug Class - PD-1 / PD-L1 Inhibitors, HER2 Antagonists, VEGFR2 Antagonists and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 343: Argentina 15-Year Perspective for Gastric Cancer by Drug Class - Percentage Breakdown of Value Sales for PD-1 / PD-L1 Inhibitors, HER2 Antagonists, VEGFR2 Antagonists and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 344: Argentina Recent Past, Current & Future Analysis for Gastric Cancer by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 345: Argentina Historic Review for Gastric Cancer by Administration Route - Oral and Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 346: Argentina 15-Year Perspective for Gastric Cancer by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2015, 2025 & 2030
  • TABLE 347: Argentina Recent Past, Current & Future Analysis for Gastric Cancer by Distribution Channel - Specialty & Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 348: Argentina Historic Review for Gastric Cancer by Distribution Channel - Specialty & Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 349: Argentina 15-Year Perspective for Gastric Cancer by Distribution Channel - Percentage Breakdown of Value Sales for Specialty & Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • TABLE 350: Argentina Recent Past, Current & Future Analysis for Gastric Cancer by Treatment Type - Immunotherapy, Targeted Therapy, Chemotherapy and Radiation Therapy & Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 351: Argentina Historic Review for Gastric Cancer by Treatment Type - Immunotherapy, Targeted Therapy, Chemotherapy and Radiation Therapy & Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 352: Argentina 15-Year Perspective for Gastric Cancer by Treatment Type - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Chemotherapy and Radiation Therapy & Surgery for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 353: Brazil Recent Past, Current & Future Analysis for Gastric Cancer by Disease Type - Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 354: Brazil Historic Review for Gastric Cancer by Disease Type - Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 355: Brazil 15-Year Perspective for Gastric Cancer by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor and Other Disease Types for the Years 2015, 2025 & 2030
  • TABLE 356: Brazil Recent Past, Current & Future Analysis for Gastric Cancer by Drug Class - PD-1 / PD-L1 Inhibitors, HER2 Antagonists, VEGFR2 Antagonists and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 357: Brazil Historic Review for Gastric Cancer by Drug Class - PD-1 / PD-L1 Inhibitors, HER2 Antagonists, VEGFR2 Antagonists and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 358: Brazil 15-Year Perspective for Gastric Cancer by Drug Class - Percentage Breakdown of Value Sales for PD-1 / PD-L1 Inhibitors, HER2 Antagonists, VEGFR2 Antagonists and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 359: Brazil Recent Past, Current & Future Analysis for Gastric Cancer by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 360: Brazil Historic Review for Gastric Cancer by Administration Route - Oral and Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 361: Brazil 15-Year Perspective for Gastric Cancer by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2015, 2025 & 2030
  • TABLE 362: Brazil Recent Past, Current & Future Analysis for Gastric Cancer by Distribution Channel - Specialty & Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 363: Brazil Historic Review for Gastric Cancer by Distribution Channel - Specialty & Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 364: Brazil 15-Year Perspective for Gastric Cancer by Distribution Channel - Percentage Breakdown of Value Sales for Specialty & Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • TABLE 365: Brazil Recent Past, Current & Future Analysis for Gastric Cancer by Treatment Type - Immunotherapy, Targeted Therapy, Chemotherapy and Radiation Therapy & Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 366: Brazil Historic Review for Gastric Cancer by Treatment Type - Immunotherapy, Targeted Therapy, Chemotherapy and Radiation Therapy & Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 367: Brazil 15-Year Perspective for Gastric Cancer by Treatment Type - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Chemotherapy and Radiation Therapy & Surgery for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 368: Mexico Recent Past, Current & Future Analysis for Gastric Cancer by Disease Type - Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 369: Mexico Historic Review for Gastric Cancer by Disease Type - Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 370: Mexico 15-Year Perspective for Gastric Cancer by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor and Other Disease Types for the Years 2015, 2025 & 2030
  • TABLE 371: Mexico Recent Past, Current & Future Analysis for Gastric Cancer by Drug Class - PD-1 / PD-L1 Inhibitors, HER2 Antagonists, VEGFR2 Antagonists and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 372: Mexico Historic Review for Gastric Cancer by Drug Class - PD-1 / PD-L1 Inhibitors, HER2 Antagonists, VEGFR2 Antagonists and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 373: Mexico 15-Year Perspective for Gastric Cancer by Drug Class - Percentage Breakdown of Value Sales for PD-1 / PD-L1 Inhibitors, HER2 Antagonists, VEGFR2 Antagonists and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 374: Mexico Recent Past, Current & Future Analysis for Gastric Cancer by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 375: Mexico Historic Review for Gastric Cancer by Administration Route - Oral and Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 376: Mexico 15-Year Perspective for Gastric Cancer by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2015, 2025 & 2030
  • TABLE 377: Mexico Recent Past, Current & Future Analysis for Gastric Cancer by Distribution Channel - Specialty & Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 378: Mexico Historic Review for Gastric Cancer by Distribution Channel - Specialty & Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 379: Mexico 15-Year Perspective for Gastric Cancer by Distribution Channel - Percentage Breakdown of Value Sales for Specialty & Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • TABLE 380: Mexico Recent Past, Current & Future Analysis for Gastric Cancer by Treatment Type - Immunotherapy, Targeted Therapy, Chemotherapy and Radiation Therapy & Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 381: Mexico Historic Review for Gastric Cancer by Treatment Type - Immunotherapy, Targeted Therapy, Chemotherapy and Radiation Therapy & Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 382: Mexico 15-Year Perspective for Gastric Cancer by Treatment Type - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Chemotherapy and Radiation Therapy & Surgery for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 383: Rest of Latin America Recent Past, Current & Future Analysis for Gastric Cancer by Disease Type - Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 384: Rest of Latin America Historic Review for Gastric Cancer by Disease Type - Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 385: Rest of Latin America 15-Year Perspective for Gastric Cancer by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor and Other Disease Types for the Years 2015, 2025 & 2030
  • TABLE 386: Rest of Latin America Recent Past, Current & Future Analysis for Gastric Cancer by Drug Class - PD-1 / PD-L1 Inhibitors, HER2 Antagonists, VEGFR2 Antagonists and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 387: Rest of Latin America Historic Review for Gastric Cancer by Drug Class - PD-1 / PD-L1 Inhibitors, HER2 Antagonists, VEGFR2 Antagonists and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 388: Rest of Latin America 15-Year Perspective for Gastric Cancer by Drug Class - Percentage Breakdown of Value Sales for PD-1 / PD-L1 Inhibitors, HER2 Antagonists, VEGFR2 Antagonists and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 389: Rest of Latin America Recent Past, Current & Future Analysis for Gastric Cancer by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 390: Rest of Latin America Historic Review for Gastric Cancer by Administration Route - Oral and Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 391: Rest of Latin America 15-Year Perspective for Gastric Cancer by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2015, 2025 & 2030
  • TABLE 392: Rest of Latin America Recent Past, Current & Future Analysis for Gastric Cancer by Distribution Channel - Specialty & Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 393: Rest of Latin America Historic Review for Gastric Cancer by Distribution Channel - Specialty & Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 394: Rest of Latin America 15-Year Perspective for Gastric Cancer by Distribution Channel - Percentage Breakdown of Value Sales for Specialty & Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • TABLE 395: Rest of Latin America Recent Past, Current & Future Analysis for Gastric Cancer by Treatment Type - Immunotherapy, Targeted Therapy, Chemotherapy and Radiation Therapy & Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 396: Rest of Latin America Historic Review for Gastric Cancer by Treatment Type - Immunotherapy, Targeted Therapy, Chemotherapy and Radiation Therapy & Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 397: Rest of Latin America 15-Year Perspective for Gastric Cancer by Treatment Type - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Chemotherapy and Radiation Therapy & Surgery for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Gastric Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 398: Middle East Recent Past, Current & Future Analysis for Gastric Cancer by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 399: Middle East Historic Review for Gastric Cancer by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 400: Middle East 15-Year Perspective for Gastric Cancer by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 401: Middle East Recent Past, Current & Future Analysis for Gastric Cancer by Disease Type - Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 402: Middle East Historic Review for Gastric Cancer by Disease Type - Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 403: Middle East 15-Year Perspective for Gastric Cancer by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor and Other Disease Types for the Years 2015, 2025 & 2030
  • TABLE 404: Middle East Recent Past, Current & Future Analysis for Gastric Cancer by Drug Class - PD-1 / PD-L1 Inhibitors, HER2 Antagonists, VEGFR2 Antagonists and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 405: Middle East Historic Review for Gastric Cancer by Drug Class - PD-1 / PD-L1 Inhibitors, HER2 Antagonists, VEGFR2 Antagonists and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 406: Middle East 15-Year Perspective for Gastric Cancer by Drug Class - Percentage Breakdown of Value Sales for PD-1 / PD-L1 Inhibitors, HER2 Antagonists, VEGFR2 Antagonists and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 407: Middle East Recent Past, Current & Future Analysis for Gastric Cancer by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 408: Middle East Historic Review for Gastric Cancer by Administration Route - Oral and Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 409: Middle East 15-Year Perspective for Gastric Cancer by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2015, 2025 & 2030
  • TABLE 410: Middle East Recent Past, Current & Future Analysis for Gastric Cancer by Distribution Channel - Specialty & Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 411: Middle East Historic Review for Gastric Cancer by Distribution Channel - Specialty & Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 412: Middle East 15-Year Perspective for Gastric Cancer by Distribution Channel - Percentage Breakdown of Value Sales for Specialty & Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • TABLE 413: Middle East Recent Past, Current & Future Analysis for Gastric Cancer by Treatment Type - Immunotherapy, Targeted Therapy, Chemotherapy and Radiation Therapy & Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 414: Middle East Historic Review for Gastric Cancer by Treatment Type - Immunotherapy, Targeted Therapy, Chemotherapy and Radiation Therapy & Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 415: Middle East 15-Year Perspective for Gastric Cancer by Treatment Type - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Chemotherapy and Radiation Therapy & Surgery for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 416: Iran Recent Past, Current & Future Analysis for Gastric Cancer by Disease Type - Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 417: Iran Historic Review for Gastric Cancer by Disease Type - Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 418: Iran 15-Year Perspective for Gastric Cancer by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor and Other Disease Types for the Years 2015, 2025 & 2030
  • TABLE 419: Iran Recent Past, Current & Future Analysis for Gastric Cancer by Drug Class - PD-1 / PD-L1 Inhibitors, HER2 Antagonists, VEGFR2 Antagonists and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 420: Iran Historic Review for Gastric Cancer by Drug Class - PD-1 / PD-L1 Inhibitors, HER2 Antagonists, VEGFR2 Antagonists and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 421: Iran 15-Year Perspective for Gastric Cancer by Drug Class - Percentage Breakdown of Value Sales for PD-1 / PD-L1 Inhibitors, HER2 Antagonists, VEGFR2 Antagonists and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 422: Iran Recent Past, Current & Future Analysis for Gastric Cancer by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 423: Iran Historic Review for Gastric Cancer by Administration Route - Oral and Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 424: Iran 15-Year Perspective for Gastric Cancer by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2015, 2025 & 2030
  • TABLE 425: Iran Recent Past, Current & Future Analysis for Gastric Cancer by Distribution Channel - Specialty & Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 426: Iran Historic Review for Gastric Cancer by Distribution Channel - Specialty & Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 427: Iran 15-Year Perspective for Gastric Cancer by Distribution Channel - Percentage Breakdown of Value Sales for Specialty & Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • TABLE 428: Iran Recent Past, Current & Future Analysis for Gastric Cancer by Treatment Type - Immunotherapy, Targeted Therapy, Chemotherapy and Radiation Therapy & Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 429: Iran Historic Review for Gastric Cancer by Treatment Type - Immunotherapy, Targeted Therapy, Chemotherapy and Radiation Therapy & Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 430: Iran 15-Year Perspective for Gastric Cancer by Treatment Type - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Chemotherapy and Radiation Therapy & Surgery for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 431: Israel Recent Past, Current & Future Analysis for Gastric Cancer by Disease Type - Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 432: Israel Historic Review for Gastric Cancer by Disease Type - Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 433: Israel 15-Year Perspective for Gastric Cancer by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor and Other Disease Types for the Years 2015, 2025 & 2030
  • TABLE 434: Israel Recent Past, Current & Future Analysis for Gastric Cancer by Drug Class - PD-1 / PD-L1 Inhibitors, HER2 Antagonists, VEGFR2 Antagonists and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 435: Israel Historic Review for Gastric Cancer by Drug Class - PD-1 / PD-L1 Inhibitors, HER2 Antagonists, VEGFR2 Antagonists and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 436: Israel 15-Year Perspective for Gastric Cancer by Drug Class - Percentage Breakdown of Value Sales for PD-1 / PD-L1 Inhibitors, HER2 Antagonists, VEGFR2 Antagonists and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 437: Israel Recent Past, Current & Future Analysis for Gastric Cancer by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 438: Israel Historic Review for Gastric Cancer by Administration Route - Oral and Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 439: Israel 15-Year Perspective for Gastric Cancer by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2015, 2025 & 2030
  • TABLE 440: Israel Recent Past, Current & Future Analysis for Gastric Cancer by Distribution Channel - Specialty & Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 441: Israel Historic Review for Gastric Cancer by Distribution Channel - Specialty & Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 442: Israel 15-Year Perspective for Gastric Cancer by Distribution Channel - Percentage Breakdown of Value Sales for Specialty & Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • TABLE 443: Israel Recent Past, Current & Future Analysis for Gastric Cancer by Treatment Type - Immunotherapy, Targeted Therapy, Chemotherapy and Radiation Therapy & Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 444: Israel Historic Review for Gastric Cancer by Treatment Type - Immunotherapy, Targeted Therapy, Chemotherapy and Radiation Therapy & Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 445: Israel 15-Year Perspective for Gastric Cancer by Treatment Type - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Chemotherapy and Radiation Therapy & Surgery for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 446: Saudi Arabia Recent Past, Current & Future Analysis for Gastric Cancer by Disease Type - Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 447: Saudi Arabia Historic Review for Gastric Cancer by Disease Type - Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 448: Saudi Arabia 15-Year Perspective for Gastric Cancer by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor and Other Disease Types for the Years 2015, 2025 & 2030
  • TABLE 449: Saudi Arabia Recent Past, Current & Future Analysis for Gastric Cancer by Drug Class - PD-1 / PD-L1 Inhibitors, HER2 Antagonists, VEGFR2 Antagonists and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 450: Saudi Arabia Historic Review for Gastric Cancer by Drug Class - PD-1 / PD-L1 Inhibitors, HER2 Antagonists, VEGFR2 Antagonists and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 451: Saudi Arabia 15-Year Perspective for Gastric Cancer by Drug Class - Percentage Breakdown of Value Sales for PD-1 / PD-L1 Inhibitors, HER2 Antagonists, VEGFR2 Antagonists and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 452: Saudi Arabia Recent Past, Current & Future Analysis for Gastric Cancer by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 453: Saudi Arabia Historic Review for Gastric Cancer by Administration Route - Oral and Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 454: Saudi Arabia 15-Year Perspective for Gastric Cancer by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2015, 2025 & 2030
  • TABLE 455: Saudi Arabia Recent Past, Current & Future Analysis for Gastric Cancer by Distribution Channel - Specialty & Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 456: Saudi Arabia Historic Review for Gastric Cancer by Distribution Channel - Specialty & Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 457: Saudi Arabia 15-Year Perspective for Gastric Cancer by Distribution Channel - Percentage Breakdown of Value Sales for Specialty & Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • TABLE 458: Saudi Arabia Recent Past, Current & Future Analysis for Gastric Cancer by Treatment Type - Immunotherapy, Targeted Therapy, Chemotherapy and Radiation Therapy & Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 459: Saudi Arabia Historic Review for Gastric Cancer by Treatment Type - Immunotherapy, Targeted Therapy, Chemotherapy and Radiation Therapy & Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 460: Saudi Arabia 15-Year Perspective for Gastric Cancer by Treatment Type - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Chemotherapy and Radiation Therapy & Surgery for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 461: UAE Recent Past, Current & Future Analysis for Gastric Cancer by Disease Type - Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 462: UAE Historic Review for Gastric Cancer by Disease Type - Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 463: UAE 15-Year Perspective for Gastric Cancer by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor and Other Disease Types for the Years 2015, 2025 & 2030
  • TABLE 464: UAE Recent Past, Current & Future Analysis for Gastric Cancer by Drug Class - PD-1 / PD-L1 Inhibitors, HER2 Antagonists, VEGFR2 Antagonists and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 465: UAE Historic Review for Gastric Cancer by Drug Class - PD-1 / PD-L1 Inhibitors, HER2 Antagonists, VEGFR2 Antagonists and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 466: UAE 15-Year Perspective for Gastric Cancer by Drug Class - Percentage Breakdown of Value Sales for PD-1 / PD-L1 Inhibitors, HER2 Antagonists, VEGFR2 Antagonists and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 467: UAE Recent Past, Current & Future Analysis for Gastric Cancer by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 468: UAE Historic Review for Gastric Cancer by Administration Route - Oral and Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 469: UAE 15-Year Perspective for Gastric Cancer by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2015, 2025 & 2030
  • TABLE 470: UAE Recent Past, Current & Future Analysis for Gastric Cancer by Distribution Channel - Specialty & Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 471: UAE Historic Review for Gastric Cancer by Distribution Channel - Specialty & Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 472: UAE 15-Year Perspective for Gastric Cancer by Distribution Channel - Percentage Breakdown of Value Sales for Specialty & Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • TABLE 473: UAE Recent Past, Current & Future Analysis for Gastric Cancer by Treatment Type - Immunotherapy, Targeted Therapy, Chemotherapy and Radiation Therapy & Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 474: UAE Historic Review for Gastric Cancer by Treatment Type - Immunotherapy, Targeted Therapy, Chemotherapy and Radiation Therapy & Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 475: UAE 15-Year Perspective for Gastric Cancer by Treatment Type - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Chemotherapy and Radiation Therapy & Surgery for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 476: Rest of Middle East Recent Past, Current & Future Analysis for Gastric Cancer by Disease Type - Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 477: Rest of Middle East Historic Review for Gastric Cancer by Disease Type - Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 478: Rest of Middle East 15-Year Perspective for Gastric Cancer by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor and Other Disease Types for the Years 2015, 2025 & 2030
  • TABLE 479: Rest of Middle East Recent Past, Current & Future Analysis for Gastric Cancer by Drug Class - PD-1 / PD-L1 Inhibitors, HER2 Antagonists, VEGFR2 Antagonists and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 480: Rest of Middle East Historic Review for Gastric Cancer by Drug Class - PD-1 / PD-L1 Inhibitors, HER2 Antagonists, VEGFR2 Antagonists and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 481: Rest of Middle East 15-Year Perspective for Gastric Cancer by Drug Class - Percentage Breakdown of Value Sales for PD-1 / PD-L1 Inhibitors, HER2 Antagonists, VEGFR2 Antagonists and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 482: Rest of Middle East Recent Past, Current & Future Analysis for Gastric Cancer by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 483: Rest of Middle East Historic Review for Gastric Cancer by Administration Route - Oral and Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 484: Rest of Middle East 15-Year Perspective for Gastric Cancer by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2015, 2025 & 2030
  • TABLE 485: Rest of Middle East Recent Past, Current & Future Analysis for Gastric Cancer by Distribution Channel - Specialty & Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 486: Rest of Middle East Historic Review for Gastric Cancer by Distribution Channel - Specialty & Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 487: Rest of Middle East 15-Year Perspective for Gastric Cancer by Distribution Channel - Percentage Breakdown of Value Sales for Specialty & Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • TABLE 488: Rest of Middle East Recent Past, Current & Future Analysis for Gastric Cancer by Treatment Type - Immunotherapy, Targeted Therapy, Chemotherapy and Radiation Therapy & Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 489: Rest of Middle East Historic Review for Gastric Cancer by Treatment Type - Immunotherapy, Targeted Therapy, Chemotherapy and Radiation Therapy & Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 490: Rest of Middle East 15-Year Perspective for Gastric Cancer by Treatment Type - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Chemotherapy and Radiation Therapy & Surgery for the Years 2015, 2025 & 2030
• AFRICA
  • Gastric Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 491: Africa Recent Past, Current & Future Analysis for Gastric Cancer by Disease Type - Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 492: Africa Historic Review for Gastric Cancer by Disease Type - Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 493: Africa 15-Year Perspective for Gastric Cancer by Disease Type - Percentage Breakdown of Value Sales for Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor and Other Disease Types for the Years 2015, 2025 & 2030
  • TABLE 494: Africa Recent Past, Current & Future Analysis for Gastric Cancer by Drug Class - PD-1 / PD-L1 Inhibitors, HER2 Antagonists, VEGFR2 Antagonists and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 495: Africa Historic Review for Gastric Cancer by Drug Class - PD-1 / PD-L1 Inhibitors, HER2 Antagonists, VEGFR2 Antagonists and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 496: Africa 15-Year Perspective for Gastric Cancer by Drug Class - Percentage Breakdown of Value Sales for PD-1 / PD-L1 Inhibitors, HER2 Antagonists, VEGFR2 Antagonists and Other Drug Classes for the Years 2015, 2025 & 2030
  • TABLE 497: Africa Recent Past, Current & Future Analysis for Gastric Cancer by Administration Route - Oral and Injectable - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 498: Africa Historic Review for Gastric Cancer by Administration Route - Oral and Injectable Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 499: Africa 15-Year Perspective for Gastric Cancer by Administration Route - Percentage Breakdown of Value Sales for Oral and Injectable for the Years 2015, 2025 & 2030
  • TABLE 500: Africa Recent Past, Current & Future Analysis for Gastric Cancer by Distribution Channel - Specialty & Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 501: Africa Historic Review for Gastric Cancer by Distribution Channel - Specialty & Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 502: Africa 15-Year Perspective for Gastric Cancer by Distribution Channel - Percentage Breakdown of Value Sales for Specialty & Retail Pharmacies, Hospital Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
  • TABLE 503: Africa Recent Past, Current & Future Analysis for Gastric Cancer by Treatment Type - Immunotherapy, Targeted Therapy, Chemotherapy and Radiation Therapy & Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 504: Africa Historic Review for Gastric Cancer by Treatment Type - Immunotherapy, Targeted Therapy, Chemotherapy and Radiation Therapy & Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 505: Africa 15-Year Perspective for Gastric Cancer by Treatment Type - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Chemotherapy and Radiation Therapy & Surgery for the Years 2015, 2025 & 2030

IV. COMPETITION